These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

725 related articles for article (PubMed ID: 20065189)

  • 1. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
    Wells SA; Gosnell JE; Gagel RF; Moley J; Pfister D; Sosa JA; Skinner M; Krebs A; Vasselli J; Schlumberger M
    J Clin Oncol; 2010 Feb; 28(5):767-72. PubMed ID: 20065189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
    Robinson BG; Paz-Ares L; Krebs A; Vasselli J; Haddad R
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2664-71. PubMed ID: 20371662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
    Fox E; Widemann BC; Chuk MK; Marcus L; Aikin A; Whitcomb PO; Merino MJ; Lodish M; Dombi E; Steinberg SM; Wells SA; Balis FM
    Clin Cancer Res; 2013 Aug; 19(15):4239-48. PubMed ID: 23766359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
    Lam ET; Ringel MD; Kloos RT; Prior TW; Knopp MV; Liang J; Sammet S; Hall NC; Wakely PE; Vasko VV; Saji M; Snyder PJ; Wei L; Arbogast D; Collamore M; Wright JJ; Moley JF; Villalona-Calero MA; Shah MH
    J Clin Oncol; 2010 May; 28(14):2323-30. PubMed ID: 20368568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].
    Chougnet CN; Schlumberger M; Leboulleux S; Baudin E
    Bull Cancer; 2014 Sep; 101(9):891-5. PubMed ID: 25296193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vandetanib and the management of advanced medullary thyroid cancer.
    Campbell MJ; Seib CD; Gosnell J
    Curr Opin Oncol; 2013 Jan; 25(1):39-43. PubMed ID: 23202050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and safety of vandetanib on advanced medullary thyroid carcinoma: single center result from a phase Ⅲ study].
    Wang SX; Zhang XW; Wang XX; An CM; Zhang YB; Liu W; Zhao YF; He XH; Li ZJ; Niu LJ; Tang PZ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jun; 54(6):439-444. PubMed ID: 31262109
    [No Abstract]   [Full Text] [Related]  

  • 8. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
    Chougnet CN; Borget I; Leboulleux S; de la Fouchardiere C; Bonichon F; Criniere L; Niccoli P; Bardet S; Schneegans O; Zanetta S; Schvartz C; Drui D; Chauffert B; Rohmer V; Schlumberger M
    Thyroid; 2015 Apr; 25(4):386-91. PubMed ID: 25627619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.
    Uchino K; Komoda M; Tomomatsu J; Okamoto T; Horiuchi K; Tsuji A; Ito Y; Todo T; Rito K; Takahashi S
    Endocr Pract; 2017 Feb; 23(2):149-156. PubMed ID: 27819766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective use of vandetanib in the treatment of thyroid cancer.
    Fallahi P; Di Bari F; Ferrari SM; Spisni R; Materazzi G; Miccoli P; Benvenga S; Antonelli A
    Drug Des Devel Ther; 2015; 9():3459-70. PubMed ID: 26170630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.
    Johanson V; Ahlman H; Bernhardt P; Jansson S; Kölby L; Persson F; Stenman G; Swärd C; Wängberg B; Stridsberg M; Nilsson O
    Endocr Relat Cancer; 2007 Jun; 14(2):433-44. PubMed ID: 17639056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
    Wells SA; Robinson BG; Gagel RF; Dralle H; Fagin JA; Santoro M; Baudin E; Elisei R; Jarzab B; Vasselli JR; Read J; Langmuir P; Ryan AJ; Schlumberger MJ
    J Clin Oncol; 2012 Jan; 30(2):134-41. PubMed ID: 22025146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vandetanib: in medullary thyroid cancer.
    Frampton JE
    Drugs; 2012 Jul; 72(10):1423-36. PubMed ID: 22715896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients.
    Tiedje V; Ting S; Walter RF; Herold T; Worm K; Badziong J; Zwanziger D; Schmid KW; Führer D
    Eur J Endocrinol; 2016 Sep; 175(3):173-80. PubMed ID: 27283290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
    Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
    Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
    [No Abstract]   [Full Text] [Related]  

  • 16. Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.
    Kraft IL; Akshintala S; Zhu Y; Lei H; Derse-Anthony C; Dombi E; Steinberg SM; Lodish M; Waguespack SG; Kapustina O; Fox E; Balis FM; Merino MJ; Meltzer PS; Glod JW; Shern JF; Widemann BC
    Clin Cancer Res; 2018 Feb; 24(4):753-765. PubMed ID: 29187393
    [No Abstract]   [Full Text] [Related]  

  • 17. Vandetanib therapy in medullary thyroid cancer.
    Grabowski P; Briest F; Baum RP; Zaknun JJ; Kulkarni HR; Zeitz M; Hörsch D
    Drugs Today (Barc); 2012 Nov; 48(11):723-33. PubMed ID: 23170308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
    Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
    Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
    Zhang L; Li S; Zhang Y; Zhan J; Zou BY; Smith R; Martin PD; Jiang Y; Liao H; Guan Z
    Clin Ther; 2011 Mar; 33(3):315-27. PubMed ID: 21600385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vandetanib for the treatment of medullary thyroid cancer.
    Chau NG; Haddad RI
    Clin Cancer Res; 2013 Feb; 19(3):524-9. PubMed ID: 23231950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.